Gary Ingenito - Jun 21, 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Medical & Reg. Officer
Signature
/s/ Gary Ingenito
Stock symbol
CPRX
Transactions as of
Jun 21, 2022
Transactions value $
-$369,824
Form type
4
Date filed
6/23/2022, 05:02 PM
Previous filing
Feb 16, 2022
Next filing
Sep 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $594K +144K +652.28% $4.13 166K Jun 21, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$949K -144K -86.71% $6.60 22.1K Jun 21, 2022 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $25.4K +6.15K +27.9% $4.13 28.2K Jun 22, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$40.6K -6.15K -21.81% $6.61 22.1K Jun 22, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -144K -11.77% $0.00 1.08M Jun 21, 2022 Common Stock 144K $4.13 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -6.15K -0.57% $0.00 1.07M Jun 22, 2022 Common Stock 6.15K $4.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Ingenito sold the shares on the open market for personal reasons and not as a result of any disagreement with the Registrant. Dr. Ingenito remains an officer of the Company.
F2 Shares were sold in various lots from $6.55 to $6.68 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $6.55 to $6.71 per share. The listed sale price represents a weighted average price for the shares sold.
F4 Options vested in three annual tranches beginning on June 30, 2016.